Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 3
2014 7
2015 7
2016 7
2017 6
2018 4
2019 8
2020 5
2021 7
2022 4
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N, Scarsi KK, Baker P, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Van Schalkwyk M, Kayama C, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R, Haas DW; AIDS Clinical Trials Group A5375 Study Team. Agyemang N, et al. Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. Epub 2023 Jun 12. Pharmacogenet Genomics. 2023. PMID: 37306344 Free PMC article.
A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035).
Bauermeister JA, Dominguez Islas C, Jiao Y, Tingler R, Brown E, Zemanek J, Giguere R, Balan I, Johnson S, Macagna N, Lucas J, Rose M, Jacobson C, Collins C, Livant E, Singh D, Ho K, Hoesley C, Liu A, Kayange N, Palanee-Phillips T, Chariyalertsak S, Gonzales P, Piper J; MTN-035 Protocol Team. Bauermeister JA, et al. PLoS One. 2023 Apr 12;18(4):e0284339. doi: 10.1371/journal.pone.0284339. eCollection 2023. PLoS One. 2023. PMID: 37043527 Free PMC article. Clinical Trial.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH. Marzinke MA, et al. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0005323. doi: 10.1128/aac.00053-23. Epub 2023 Mar 30. Antimicrob Agents Chemother. 2023. PMID: 36995219 Free PMC article.
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial.
Cherkos AS, LaCourse SM, Enquobahrie DA, Richardson BA, Bradford S, Montepiedra G, Mmbaga BT, Mbengeranwa T, Masheto G, Jean-Phillippe P, Chakhtoura N, Theron G, Weinberg A, Cassim H, Raesi MS, Jean E, Wabwire D, Nematadzira T, Stranix-Chibanda L, Hesseling AC, Aurpibul L, Gupta A, John-Stewart G; IMPAACT P1078 TB APPRISE Study Team. Cherkos AS, et al. EClinicalMedicine. 2023 Mar 17;58:101912. doi: 10.1016/j.eclinm.2023.101912. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 36969345 Free PMC article.
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.
Lalloo UG, Komarow L, Aberg JA, Clifford DB, Hogg E, McKhann A, Bukuru A, Lagat D, Pillay S, Mave V, Supparatpinyo K, Samaneka W, Langat D, Ticona E, Badal-Faesen S, Larsen RA; ACTG A5225 Team. Lalloo UG, et al. PLoS One. 2023 Feb 13;18(2):e0281580. doi: 10.1371/journal.pone.0281580. eCollection 2023. PLoS One. 2023. PMID: 36780493 Free PMC article. Clinical Trial.
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Scarsi KK, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R; AIDS Clinical Trials Group A5375 Study Team. Scarsi KK, et al. Contraception. 2023 May;121:109951. doi: 10.1016/j.contraception.2023.109951. Epub 2023 Jan 12. Contraception. 2023. PMID: 36641094 Free PMC article. Clinical Trial.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM; IMPAACT 2014 study team. Melvin AJ, et al. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. doi: 10.1097/QAI.0000000000003116. J Acquir Immune Defic Syndr. 2023. PMID: 36215957 Free PMC article.
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Pham MM, Podany AT, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, Samaneka W, Omoz-Oarhe A, Langat D, Benson CA, Chaisson RE, Swindells S, Fletcher CV. Pham MM, et al. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0238521. doi: 10.1128/aac.02385-21. Epub 2022 Aug 9. Antimicrob Agents Chemother. 2022. PMID: 35943252 Free PMC article.
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, Popson S, Buchanan AM, Bartlett M, Dayton D, Anthony P, Brothers C, Vavro C, Singh R, Koech L, Vhembo T, Mmbaga BT, Pinto JA, Dobbels EFM, Archary M, Chokephaibulkit K, Ounchanum P, Deville JG, Hazra R, Townley E, Wiznia A; IMPAACT P1093 team. Ruel TD, et al. Lancet HIV. 2022 May;9(5):e332-e340. doi: 10.1016/S2352-3018(22)00044-3. Lancet HIV. 2022. PMID: 35489377 Free PMC article. Clinical Trial.
68 results